The DMA Cocktail: How a 3-Drug Combo Targets Cancer and Senescent Cells Together
Dr. Irina Conboy walks through a study in which a three-drug cocktail called DMA extended the remaining life expectancy of old mice by roughly 41% from the start of treatment. The approach selectively eliminates cancer and senescent cells by exploiting their shared reliance on glycolysis, while sparing healthy cells. She stresses the work is early-stage and not a basis for biohacking.
Overview
In this conversation with Modern Healthspan, Dr. Irina Conboy, former UC Berkeley professor and co-founder of Generation Lab, discusses a recently published study on selectively targeting cancer and senescent cells through their shared metabolic changes. The headline figure, a 41.7% increase in life expectancy, applies to old mice counted from the first treatment, and is closer to 10 to 12% across the whole lifespan.
What makes the result notable is that this came from a chemotherapeutic and senolytic cocktail that did not increase frailty, unlike conventional chemotherapy. The cocktail, called DMA, combines dichloroacetate, metformin, and ABT-263 (navitoclax). Its logic rests on a shared weakness: both cancer and senescent cells have damaged mitochondria and lean on glycolysis to survive.
DCA forces pyruvate into the mitochondria, metformin throttles the electron transport chain, and low-dose navitoclax blocks the BCL survival proteins so stressed cells undergo programmed cell death. Healthy cells, with more and better mitochondria, tolerate the combination. Conboy also revisits neutral blood exchange and a Generation Lab injectable designed to recalibrate age-elevated blood proteins. Throughout, she cautions that the doses are theoretical, tested in human cells and mice, and not ready for people to replicate.
Key quotes
5From that point on, they lived 41.7% longer.
It's not just another longevity therapy. It is a new class of therapy that is chemotherapeutic, so it eliminates cancer cells and prevents cancer. It also eliminates senescent cells, but unlike other approaches, it does not induce frailty.
Their weakness is that they have altered mitochondria or their ability to produce ATP.
We use 1/10 of that dose because we have two other drugs that already push cancerous and senescent cells to their limits.
For now, I wouldn't recommend that people do any kind of biohacking.
Key ideas
9The 41% figure in context
The 41.7% life-expectancy gain is measured from the first treatment in old mice, not across the whole lifespan. Counted from birth, the increase is closer to 10 to 12%.
A new therapeutic class, not just a longevity drug
The cocktail is chemotherapeutic and senolytic, yet it extended life without the frailty that usually follows chemotherapy. Conboy frames this as a distinct therapeutic class.
Treatment started in old mice
The mice were 18 to 20 months old when treated, roughly analogous to a person aged 65 to 70. The goal was to extend remaining life from an already-aged starting point.
Function preserved, not just lifespan
Overall frailty score was unchanged and treadmill endurance improved, with no decline on the agility suspension test. For a potent chemo-senolytic mix, the absence of added frailty is itself the finding.
What DMA stands for
DMA combines dichloroacetate (D), metformin (M), and ABT-263 / navitoclax (A). Metformin is a known longevity and diabetes drug; navitoclax inhibits BCL survival proteins to enable apoptosis.
Why target cancer and senescence together
Senescent cells secrete inflammatory SASP factors that create a permissive environment where cancer thrives. Removing both at once denies cancer that supportive niche.
The shared glycolysis weakness (Warburg effect)
Both cell types have damaged mitochondria and rely on glycolysis for ATP. At least half of cancers show this Warburg switch, making it a broad, shared vulnerability.
The apoptosis mechanism
DCA forces pyruvate into mitochondria, metformin inhibits the electron transport chain, and navitoclax blocks BCL proteins so cytochrome c leaks and triggers programmed cell death in the stressed cells.
Beyond DMA: an injectable blood-recalibration drug
Generation Lab is developing a subcutaneous injectable to substitute for neutral blood exchange, aiming to inactivate age-elevated blood proteins and promote tissue repair.
Practical takeaways
6- 1
Read lifespan numbers by their baseline 6:00
A 41% gain from the first treatment is not the same as 41% over a full lifespan. Always ask what point the clock starts from when comparing longevity claims.
- 2
Healthspan is more than years 19:30
Preserving physical function and avoiding added frailty can matter as much as the lifespan number, especially for therapies that are also chemotherapeutic.
- 3
Selectivity can come from dose and combination 41:00
Using one-tenth of the usual navitoclax dose alongside two other drugs targeted sick cells while sparing healthy ones, preserving platelet counts.
- 4
Availability is not endorsement 44:30
Dichloroacetate can be bought online and metformin is approved, but the tested doses and combination are unvalidated in people.
- 5
Plasma exchange is powerful but hard to scale 48:30
Neutral blood exchange shows benefits yet is invasive and cumulative in side effects, which is why an injectable substitute is being pursued.
- 6
Not a biohacking recipe yet 50:30
The effective doses are theoretical and demonstrated in human cell culture and mice, not in living people. Conboy explicitly advises against self-experimentation.
Topics & chapters
14A new substitute for blood exchange
Conboy previews a pharmacological agent that inactivates age-elevated blood proteins and promotes tissue repair.
Welcome back and the 41% study
Richard introduces the recent paper on selectively targeting cancer and senescence to extend lifespan in old mice.
Clarifying the lifespan numbers
The gain is 41.7% from first treatment but roughly 10 to 12% across the whole lifespan.
A chemo-senolytic that avoids frailty
Unlike conventional chemotherapy, the cocktail extended life without reducing health, defining a new therapeutic class.
Trial design and mouse age
Mice aged 18 to 20 months, analogous to humans aged 65 to 70, were treated and tracked for life expectancy.
Frailty and fitness results
Frailty score was unchanged while treadmill endurance improved and agility held steady.
Cancer in mice and next steps
C57BL/6 mice are cancer-prone; formal cancer-incidence studies are planned for a future paper.
The DMA cocktail components
Dichloroacetate, metformin, and ABT-263 (navitoclax) and what each contributes.
Targeting cancer and senescence together
Senescent cells and their SASP factors create an environment where cancer thrives, so both are removed at once.
The shared metabolic weakness
Damaged mitochondria push both cell types toward glycolysis, the common vulnerability the cocktail exploits.
The mechanism, step by step
DCA, metformin, and navitoclax combine to force apoptosis via cytochrome c leakage in stressed cells.
Low-dose navitoclax and selectivity
One-tenth of the usual dose spares platelets and healthy cells while eliminating pathogenic ones.
Neutral blood exchange and the injectable
Generation Lab works on a subcutaneous drug to recalibrate age-elevated blood proteins at scale.
FDA path, caution, and where to follow
Cardiovascular prevention is a candidate indication; Conboy warns against biohacking and points to Generation Lab in Burlingame.